You may continue taking atezolizumab and cobimetinib for as long as the study doctor thinks is in your best interest. You may receive up to 4 cycles of eribulin. You will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.